comparemela.com

Latest Breaking News On - Formycon ag - Page 2 : comparemela.com

Investegate |Formycon AG Announcements | Formycon AG: Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2

Investegate announcements from Formycon AG, Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2

Polpharma biologicsCorporate communicationsEuropean unionEuropean commissionMarket scale of the frankfurt stock exchangeGenentech incCommittee for medicinal products human useTeva pharmaceutical industries ltdHoc announcementJoint ventureTeva pharmaceutical industriesMedicinal productsHuman useOpen marketFrankfurt stock exchangeManager corporate communications

Investegate |Formycon AG Announcements | Formycon AG: Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2

Investegate announcements from Formycon AG, Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2

United statesChoroidal neovascularizationPolpharma biologics groupCorporate communicationsCoherus biosciences incMarket scale of the frankfurt stock exchangeDrug administrationGenentech incHoc announcementJoint ventureCoherus biosciencesAge related neovascularMacular degenerationDiabetic macular edemaDiabetic retinopathyMacular edema

Investegate |Formycon AG Announcements | Formycon AG: FYB201, Formycon s biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA

Investegate announcements from Formycon AG, FYB201, Formycon s biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA

European commissionGenentech incTeva pharmaceutical industries ltdEuropean unionCorporate communicationsMarket scale of the frankfurt stock exchangeEuropean medicines agencyCommittee for medicinal products human useHoc announcementMedicinal productsHuman usePharmaceutical industries ltdOpen marketFrankfurt stock exchangeManager corporate communicationsInvestegate announcements

Investegate |Formycon AG Announcements | Formycon AG: Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG

Investegate announcements from Formycon AG, Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG

United statesFrankfurt am mainCarsten brockmeyerWendeln cieBioeq gmbStefan glombitzaMelissa simonFlorian bambergAristo pharma gmbBioeq gmbhGenentech incResearch developmentStrategic communicationsSanto holding gmbCorporate communicationsFormycon group

Investegate |Formycon AG Announcements | Formycon AG: Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region

Investegate announcements from Formycon AG, Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region

Corporate communicationsCell therapy pte ltdHoc announcementConcludes collaborationLicense agreementAsia pacificTherapy pte ltdManager corporate communicationsInvestegate announcementsInvestegate company announcementsFormycon agQs and eqs

vimarsana © 2020. All Rights Reserved.